Clinical application of optical coherence elastography
Research type
Research Study
Full title
Quantitative optical coherence elastography (OCE) in clinical detection and characterisation of prostate cancer
IRAS ID
271421
Contact name
Ghulam Nabi
Contact email
Sponsor organisation
University of Dundee
Duration of Study in the UK
1 years, 6 months, 0 days
Research summary
This research is aimed to evaluate the effectiveness of Optical coherence elastography (OCE) in clinical diagnosis and characterization of prostate cancer (PCa). This OCE device was developed and built by OCT (Optical Coherence Tomography) research team, Biomedical Engineering, Department of Engineering, University of Dundee in 2013, the principle developer is Dr. Chunhui Li. Based on the results from previous OCE study on PCa biopsy (2013ON47 – 14/ES/0049 - Quantitative optical coherence elastography (OCE) in the detection and characterisation of prostate cancer), it clearly shows the potential of OCE in clinical detection of PCa. In previous OCE study, the fixed PCa biopsy is examined by OCE. For this study, the OCE will be applied in the room next to the Urology theatre. This will allow for rapid analysis and recording of data of biopsy samples taken by Urology surgeons prior to sending to pathology for full and final scan. Optical coherence elastography (OCE) is a technique which evaluate the stiffness (Young’s modulus) of tissue, by combining the high-resolution optical coherence tomography (OCT) and external mechanical stimulations (magnetic shaker). The plan is to scan fresh suspicious prostate tissue biopsies by OCE, which the fresh prostate tissue biopsies are taken from the patient by using transrectal ultrasound (TRUS) guided biopsies. The findings of OCE can be used to differentiate aggressive from indolent PCa. In the first phase, it has been planned to examine fresh PCa tissue from 60 patients and analyse the data. In the further research plan, development of the OCE system and trial recruiting a larger number of patients will be considered.
Participant numbers: We plan to recruit 60 patients with clinically localised prostate cancer over a period of 1.5 years in a protocol-based prospective cohort study.REC name
South East Scotland REC 01
REC reference
20/SS/0030
Date of REC Opinion
8 Jun 2020
REC opinion
Further Information Favourable Opinion